Lee K, Majumdar M K, Buyaner D, Hendricks J K, Pittenger M F, Mosca J D
Osiris Therapeutics, Inc., 2001 Aliceanna Street, Baltimore, Maryland 21231-2001, USA.
Mol Ther. 2001 Jun;3(6):857-66. doi: 10.1006/mthe.2001.0327.
Human adult bone marrow contains both hematopoietic stem cells that generate cells of all hematopoietic lineages and human mesenchymal stem cells (hMSCs), which support hematopoiesis and contribute to the regeneration of multiple connective tissues. The goal of the current study was to demonstrate that transduced hMSCs maintain transgene expression after stem cell differentiation in vitro and in vivo. We have introduced genes into cultured hMSCs by retroviral vector transfer and demonstrated long-term in vitro and in vivo expression of human interleukin 3 (hIL-3) and green fluorescent protein (GFP). Protocols were developed to achieve transduction efficiencies of 80-90% in these stem cells. In vitro expression of hIL-3 averaged 350 ng/10(6)cells/24 h over 17 passages (> 6 months) and GFP expression was stable over the same time period. Transduced hMSCs were able to differentiate into osteogenic, adipogenic, and chondrogenic lineages and maintained transgene expression after differentiation. Parallel studies were performed in vivo using NOD/SCID mice. Human MSCs expressing hIL-3 were cultured on several matrices and then delivered by subcutaneous, intravenous, and intraperitoneal routes. Sampling of peripheral blood demonstrated that systemic hIL-3 expression was maintained in the range of 100-800 pg/ml over a period of 3 months. These results illustrate the ability of hMSCs to express genes of therapeutic potential and demonstrate their potential clinical utility as cellular vehicles for systemic gene delivery.
人类成人骨髓中既含有能产生所有造血谱系细胞的造血干细胞,也含有支持造血并有助于多种结缔组织再生的人间充质干细胞(hMSCs)。本研究的目的是证明转导的hMSCs在体外和体内干细胞分化后仍能维持转基因表达。我们通过逆转录病毒载体转移将基因导入培养的hMSCs,并证明了人白细胞介素3(hIL-3)和绿色荧光蛋白(GFP)在体外和体内的长期表达。已制定方案以在这些干细胞中实现80%-90%的转导效率。在超过17代(>6个月)的时间里,hIL-3的体外表达平均为350 ng/10(6)细胞/24小时,并且GFP表达在同一时期保持稳定。转导的hMSCs能够分化为成骨、成脂和成软骨谱系,并且在分化后仍维持转基因表达。使用NOD/SCID小鼠进行了体内平行研究。将表达hIL-3的人MSCs在几种基质上培养,然后通过皮下、静脉和腹腔途径递送。外周血采样表明,在3个月的时间里,全身hIL-3表达维持在100-800 pg/ml的范围内。这些结果说明了hMSCs表达具有治疗潜力基因的能力,并证明了它们作为全身基因递送细胞载体的潜在临床应用价值。